Recombinant human bone morphogenetic protein 4 (Stemgen)

N/A

Report date: 2024/10/16 17:43:58

Base Information

Drug NameRecombinant human bone morphogenetic protein 4 (Stemgen)
Drug Alias NameRecombinant human bone morphogenetic protein 4HS-214hrBMP4
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionBone morphogenetic protein receptor type-1B agonistsBone morphogenetic protein receptor type-1A stimulantsBone morphogenetic protein receptor type-2 agonists
TargetsBone morphogenetic protein receptor type-1ABone morphogenetic protein receptor type-1BBone morphogenetic protein receptor type-2
Therapy Area/IndicationsRejection of lung transplantationLung DiseasesBronchiolitis Obliterans +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsItaly +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesStemgen
China Registration ClassN/A

Develop Information

Active CompaniesStemgenTrove Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsRejection of lung transplantationLung DiseasesBronchiolitis Obliterans +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A